Search Results

Cambrex, a leading global contract development and manufacturing organization, announced that it is nearing the completion of a 5-year, $100-million-dollar investment strategy, one year ahead of schedule.

Charles River Laboratories International, Inc. announced the publication of its 2023 Corporate Citizenship Report, which includes progress and results from 2022 and 2023.

Ultragenyx Pharmaceutical Inc. today announced positive topline results from the Phase 3 GlucoGene study ( NCT05139316 ) evaluating DTX401, an investigational gene therapy for the treatment of patients aged eight years and older with glycogen storage disease type Ia (GSDIa).

Cambrex, a leading global contract development and manufacturing organization, has completed the sale of its Drug Product Business Unit to Wilmington, Delaware based Noramco.

New turnkey research facility will provide AAALAC-accredited flexible vivarium space for Massachusetts biopharmaceutical hub Charles River Laboratories International, Inc. has announced the opening of a new Charles River Accelerator and Development Lab facility on Chestnut Street in Somerville, Massachusetts, an emerging life sciences hub.

Cambrex announced it is investing in a new, 21,000-square-foot research and development facility in Minneapolis, Minnesota, expanding its capacity for small molecule development and manufacturing.

Noramco, a leading global active pharmaceutical ingredients manufacturer, specializing in controlled substances, announced it has completed the acquisition of the Cambrex Drug Product Business Unit previously known as Halo Pharmaceuticals.

AvenCell Therapeutics, Inc. today announced that it has dosed the first patient in a Phase IA study with AVC-201 for the treatment of relapsed/refractory Acute Myeloid Leukemia (AML) and other selected hematologic malignancies positive for CD123 (NCT05949125).